NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $2.92 +0.04 (+1.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.86▼$2.9250-Day Range$2.22▼$2.9252-Week Range$2.19▼$4.00Volume60,995 shsAverage Volume75,927 shsMarket Capitalization$365.77 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nautilus Biotechnology alerts: Email Address Nautilus Biotechnology MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside71.2% Upside$5.00 Price TargetShort InterestBearish1.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.68) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector671st out of 936 stocksAnalytical Instruments Industry21st out of 27 stocks 3.2 Analyst's Opinion Consensus RatingNautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageNautilus Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.56% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Nautilus Biotechnology has recently decreased by 3.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAUT. Previous Next 3.2 News and Social Media Coverage News SentimentNautilus Biotechnology has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.68) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nautilus Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Nautilus Biotechnology Stock (NASDAQ:NAUT)Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More NAUT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAUT Stock News HeadlinesJuly 23, 2024 | americanbankingnews.comNautilus Biotechnology (NAUT) Set to Announce Earnings on TuesdayJuly 9, 2024 | globenewswire.comNautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024July 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.May 1, 2024 | msn.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...May 1, 2024 | finance.yahoo.comQ1 2024 Nautilus Biotechnology Inc Earnings CallApril 30, 2024 | investorplace.comNAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q1 2024April 30, 2024 | finance.yahoo.comNautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than ExpectedJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.April 30, 2024 | msn.comNautilus Biotechnology GAAP EPS of -$0.15 beats by $0.01April 30, 2024 | globenewswire.comNautilus Biotechnology Reports First Quarter 2024 Financial ResultsApril 25, 2024 | msn.comJeff Bezos Earns So Much He Could Buy a Rolex Every Second — How Does He Make Money?April 16, 2024 | morningstar.comNautilus Biotechnology Inc Ordinary Shares NAUTApril 11, 2024 | globenewswire.comNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024March 12, 2024 | msn.comStartup Mahakumbh Redefines India's Esports and Gaming IndustryMarch 11, 2024 | finance.yahoo.comThis Nautilus Biotechnology Insider Increased Their Holding In The Last YearMarch 1, 2024 | seekingalpha.comNautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call TranscriptSee More Headlines Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+71.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.94% Return on Assets-21.70% Debt Debt-to-Equity RatioN/A Current Ratio20.09 Quick Ratio20.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.38Miscellaneous Outstanding Shares125,265,000Free Float74,533,000Market Cap$365.77 million OptionableOptionable Beta1.20 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Sujal M. Patel (Age 49)Co-Founder, CEO, President, Secretary & Director Comp: $827.24kDr. Parag Mallick Ph.D. (Age 46)Co-Founder, Chief Scientist & Director Comp: $562.8kMs. Anna Mowry (Age 40)CFO & Treasurer Comp: $519.21kMs. Mary E. Godwin (Age 65)Senior Vice President of Operations Mr. Matthew B. Murphy ESQ. (Age 59)General Counsel Comp: $382.64kMr. Chris BlessingtonVice President of Corporate Marketing & CommunicationsMs. Gwen E. Weld (Age 66)Chief People Officer Comp: $390.97kMr. Nick A. Nelson (Age 40)Chief Business Officer & Senior VP of Business Development Dr. Subra Sankar Ph.D. (Age 64)Senior Vice President of Product Development Comp: $38.47kMore ExecutivesKey CompetitorsTenaya TherapeuticsNASDAQ:TNYABioAtlaNASDAQ:BCABAffimedNASDAQ:AFMDTalaris TherapeuticsNASDAQ:TALSORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsClarius Group LLCBought 16,661 shares on 7/11/2024Ownership: 0.508%Price T Rowe Associates Inc. MDBought 4,239 shares on 5/15/2024Ownership: 0.013%Vanguard Group Inc.Bought 29,604 shares on 5/10/2024Ownership: 2.283%SG Americas Securities LLCSold 8,397 shares on 5/7/2024Ownership: 0.016%China Universal Asset Management Co. Ltd.Bought 9,624 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $2.99 at the start of the year. Since then, NAUT shares have decreased by 2.3% and is now trading at $2.92. View the best growth stocks for 2024 here. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Tuesday, April, 30th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's top institutional shareholders include Clarius Group LLC (0.51%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld, Perceptive Advisors Llc, Matthew L Posard and Matthew S Mcilwain. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAUT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
